These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 34505112)

  • 21. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.
    Bauer K; Rancea M; Roloff V; Elter T; Hallek M; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008079. PubMed ID: 23152253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
    Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP
    J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders.
    Kaegi C; Wuest B; Crowley C; Boyman O
    Front Immunol; 2021; 12():788830. PubMed ID: 35185862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
    Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL
    Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Li H; Hu F; Zhang Y; Li K
    J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ocrelizumab: A Review in Multiple Sclerosis.
    Lamb YN
    Drugs; 2022 Feb; 82(3):323-334. PubMed ID: 35192158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
    Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
    Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
    Kappos L; Li D; Calabresi PA; O'Connor P; Bar-Or A; Barkhof F; Yin M; Leppert D; Glanzman R; Tinbergen J; Hauser SL
    Lancet; 2011 Nov; 378(9805):1779-87. PubMed ID: 22047971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
    N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia.
    Alharbi MA; Aldosari F; Althobaiti AH; Abdullah FM; Aljarallah S; Alkhawajah NM; Alanazi M; AlRuthia Y
    BMC Health Serv Res; 2023 May; 23(1):552. PubMed ID: 37237257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
    Weibel S; Rücker G; Eberhart LH; Pace NL; Hartl HM; Jordan OL; Mayer D; Riemer M; Schaefer MS; Raj D; Backhaus I; Helf A; Schlesinger T; Kienbaum P; Kranke P
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012859. PubMed ID: 33075160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic treatments for eczema: a network meta-analysis.
    Sawangjit R; Dilokthornsakul P; Lloyd-Lavery A; Lai NM; Dellavalle R; Chaiyakunapruk N
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD013206. PubMed ID: 32927498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.
    Zhang J; Shi S; Zhang Y; Luo J; Xiao Y; Meng L; Yang X
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD010968. PubMed ID: 29178444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ocrelizumab: a new milestone in multiple sclerosis therapy.
    Mulero P; Midaglia L; Montalban X
    Ther Adv Neurol Disord; 2018; 11():1756286418773025. PubMed ID: 29774057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ocrelizumab for the treatment of multiple sclerosis.
    Bigaut K; De Seze J; Collongues N
    Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ocrelizumab and Other CD20
    Gelfand JM; Cree BAC; Hauser SL
    Neurotherapeutics; 2017 Oct; 14(4):835-841. PubMed ID: 28695471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.